Jannine Poletti Hughes

Dr. Jannine Poletti Hughes


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in International Review of Financial Analysis
Verified
Journal Article
Closed access
JHJannine Poletti Hughes
Jannine Poletti Hughes
GBGuadalupe C. Briano-Turrent
Guadalupe C. Briano-Turrent

1 March 2017 in International Review of Financial Analysis
Verified
Journal Article
Open access
Saeed AkbarSaeed Akbar
Saeed Akbar
BKButhiena Kharabsheh
Buthiena Kharabsheh
JHJannine Poletti Hughes
Jannine Poletti Hughes
SSSyed Zulfiqar Ali Shah
Syed Zulfiqar Ali Shah

1 September 2016 in Research in International Business and Finance
Verified
Journal Article
Open access
Saeed AkbarSaeed Akbar
Saeed Akbar
JHJannine Poletti Hughes
Jannine Poletti Hughes
RERamadan El-Faitouri
Ramadan El-Faitouri
SSSyed Zulfiqar Ali Shah
Syed Zulfiqar Ali Shah

22 July 2020 in International Journal of Finance & Economics
Verified
Journal Article
Open access
PDF file
JHJannine Poletti Hughes
Jannine Poletti Hughes
BGBeatriz Martínez Garcia
Beatriz Martínez Garcia
Grounded in the agency, socioemotional wealth and resource dependence theories, we study how debt decisions are influenced by family control and how such relationship is moderated by an internal corporate governance mechanism, the quality of the board of directors. Our results show that family‐controlled firms use more leverage at lower levels of family ownership to retain family control over the business, but once their socioemotional wealth is fulfilled at higher levels of ownership, they decrease leverage in pursuit of conservative financing policies. These actions are found to be moderated by board quality (i.e., experience and expertise) and female directors (predominantly independent).

21 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DHDyfrig Hughes
Dyfrig Hughes
JHJannine Poletti Hughes
Jannine Poletti Hughes
Concerns about the high cost of orphan drugs has led to questions being asked about the generosity of the incentives for development, and associated company profits. We conducted a retrospective, propensity score matched study of publicly-listed orphan companies. Cases were defined as holders of orphan drug market authorisation in Europe or the USA between 2000–12. Control companies were selected based on their propensity for being orphan drug market authorisation holders. We applied system General Method of Moments to test whether companies with orphan drug market authorization are valued higher, as measured by the Tobin’s Q and market to book value ratios, and are more profitable based on return on assets, than non-orphan drug companies. 86 companies with orphan drug approvals in European (4), USA (61) or both (21) markets were matched with 258 controls. Following adjustment, orphan drug market authorization holders have a 9.6% (95% confidence interval, 0.6% to 18.7%) higher return on assets than non-orphan drug companies; Tobin’s Q was higher by 9.9% (1.0% to 19.7%); market to book value by 15.7% (3.1% to 30.0%) and operating profit by 516% (CI 19.8% to 1011%). For each additional orphan drug sold, return on assets increased by 11.1% (0.6% to 21.3%), Tobin’s Q by 2.7% (0.2% to 5.2%), and market to book value ratio by 5.8% (0.7% to 10.9%). Publicly listed pharmaceutical companies that are orphan drug market authorization holders are associated with higher market value and greater profits than companies not producing treatments for rare diseases.

1 May 2019 in International Review of Financial Analysis
Verified
Journal Article
Closed access
JHJannine Poletti Hughes
Jannine Poletti Hughes
JWJonathan Williams
Jonathan Williams